Journal Mobile Options
Table of Contents
Vol. 25, No. 4-6, 1999
Issue release date: July–December 1999
Miner Electrolyte Metab 1999;25:349–351
(DOI:10.1159/000057473)

Vitamin Replacement Therapy in Renal Failure Patients

Makoff R.
R & D Laboratories, Inc, Marina del Rey, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Renal failure patients require vitamin replacement therapy that addresses the specialized needs of renal failure. Four factors including restricted diet, uremic toxins, drug-nutrient interactions, and in ESRD, the dialysis process, affect the normal absorption, retention and activity of necessary micronutrients which support all aspects of carbohydrate, protein, lipid and nucleic acid metabolism. Studies have shown that the typical renal failure diet is low in B vitamins, that uremic factors affect folate and pyridoxine activities and that many B vitamins are lost on dialysis at a rate greater than are lost with normal urinary excretion. In addition, retention of vitamin A or inappropriately high supplementation of vitamin C may cause toxicities which exacerbate existing pathologies. Further, emerging research suggests some vitamins such as folic acid and pyridoxine, if provided in higher than normal amounts, may have an impact on reducing the risk of some aspects of renal cardiovascular disease. It is therefore important to supplement some vitamins, and use restraint in the supplementation of others. It is clear that renal failure patients, including predialysis, ESRD and transplant patients need specialized supplementation that meets the requirements of disease and its management.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rocco M, Makoff R: Appropriate vitamin therapy for dialysis patients. Semin Dial 1997;10:272–277.
  2. Stein G, Sperschneider S, Doppe S: Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 1985;3:52–62.

    External Resources

  3. Waxman S, Corcino JJ, Herbert V: Drugs, toxins and dietary amino acids affecting vitamin B12 or folic acid absorption or utilization. Am J Med 1970;48:599–608.

    External Resources

  4. Drueke TB: Resistance to recombinant human erythropoietin in hemodialysis patients. Am J Nephrol 1990;10(suppl 2):34–39.
  5. Hartoff WE, Ridout JH, Sellers EA, et al: Atheromatous changes in aorta, carotid and coronary arteries of choline deficient rats. Proc Soc Exp Biol Med 1952;81:384–393.
  6. Nygård O, Vollset SE, Refsum H, et al: Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study. JAMA 1995;274:1526–1533.
  7. Makoff R, Dwyer J, Rocco MV: Folic acid, pyridoxine, cobalamin and homocysteine and their relationship to cardiovascular disease in end‐stage renal disease. J Ren Nutr 1996;6:2–11.
  8. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230–234.
  9. Westhuyzen J, Matherson K, Tracey R, Fleming SJ: Effect of withdrawal of folic acid supple‐ mentation in maintenance hemodialysis patients. Clin Nephrol 1993;40:96–99.
  10. Stone WJ, Warnock LG, Wagner C: Vitamin B6 deficiency in uremia. Am J Clin Nutr 1975;28:950–957.

    External Resources

  11. Kopple JD, Mercurio K, Blumenkrantz MJ, et al: Daily requirements for pyridoxine supplementation in chronic renal failure. Kidney Int 1981;19:694–704.

    External Resources

  12. Ross EA, Shah GM, Reynolds RD, Sabo A, Pichon M: Vitamin B6 requirements of patients on chronic peritoneal dialysis. Kidney Int 1989;36:702–706.

    External Resources

  13. Kelly MP, Kight MA, Don BR, Castillo S, Migliore B: Evaluation of pyridoxal phosphate/B6 status (abstract). J Ren Nutr 1997.
  14. Papastephanidis C, Agroyannis B, Tzanatos‐Exarchou H, Orthopoulos B, Koutsicos D, Frangos‐Plemenos M, Kallitsis M, Yatzidis H: Re‐evaluation of ascorbic deficiency in hemodialysed patients. Int Artif Organs 1987;10:163–165.
  15. Sullivan JF, Eisenstein AB: Ascorbic acid depletion in patients during hemodialysis. Am J Clin Nutr 1970;23:1339–1346.

    External Resources

  16. Thompson CS, Weinman EJ: The secondary oxalosis of renal failure. Semin Dial 1988;1:94–99.
  17. Kopple J: Nutrition, diet, and the kidney; in Shills ME, Olson JA, Shike M (eds): Modern Nutrition in Health and Disease, ed 8. Philadelphia, Lea & Febiger Malvern, 1994, pp 1102–1134.
  18. Paskalev D, Jankova T, Tschankova P, Steiner M, Nenov D: Increase of plasma and red blood cell vitamin E concentration in uremic patients on maintenance haemodialysis undergoing treatment with recombinant erythropoietin (letter). Nephrol Dial Transplant 1993;8:1187–1188.
  19. Muth I: Implications of hypervitaminosis A in chronic renal failure. J Renal Nutrition 1991;1:2–8.
  20. Duffy TP: Remembering the ABC’s. N Engl J Med 1994;330:994–996.
  21. Pastor MC, Sierra C, Bonal J, Teixido J: Serum and erythrocyte tocopherol in uremic patients: Effect of hemodialysis versus peritoneal dialysis. Am J Nephrol 1993;13:238–243.
  22. Ono K: Effects of large dose vitamin E supplementation of anemia in hemodialysis patients. Nephron 1985;40:440–445.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00